Organization (Other)
Biobizkaia Health Research Institute
ClinicalTrials.gov lists Biobizkaia Health Research Institute as lead sponsor of 10 trials. It has 4 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Biobizkaia Health Research Institute: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (29)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 2 |
| Anemia | 1 |
| Atherosclerosis | 1 |
| COVID-19 | 1 |
| Chronic Pain | 1 |
Showing 5 of 29 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 2 |
| 2017 | 1 |
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| betamethasone and Ropivacaine | Pain | Phase 3 | 1 |
| betamethasone and Ropivacaine | Chronic Pain | Phase 3 | 1 |
| Platelet-rich Plasma Local injection | Pain | Phase 3 | 1 |
| Platelet-rich Plasma Local injection | Chronic Pain | Phase 3 | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ferric Carboxymaltose Injection [Injectafer] | 1 |
| Vabysmo 6 MG in 0.05 ML Injection | 1 |
Journals published in (190)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Lancet (London, England) | 6 |
| Circulation | 4 |
| European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery | 4 |
| Frontiers in public health | 4 |
| Journal of perinatology : official journal of the California Perinatal Association | 4 |
Showing 5 of 190 journals.
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hospital Infanta Sofia | Co sponsors trial with | 1 |
| Germans Trias i Pujol Hospital | Co sponsors trial with | 1 |
| Sociedad Espanola de Angiologia y Cirugia Vascular | Co sponsors trial with | 1 |
| Hospital Universitario La Fe | Co sponsors trial with | 1 |
| Fundació Institut Germans Trias i Pujol | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (27)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 27 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ATP12A | Trial collaborator | Named in trial inclusion criteria |
| ATP4A | Trial collaborator | Named in trial inclusion criteria |
| PIP | Trial collaborator | Named in trial inclusion criteria |
| ATP12A | Trial collaborator | Mentioned in trial text |
| ATP4A | Trial collaborator | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.